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Abstract: An efficient and concise synthesis of nine populene D analogues was performed 
using an iodine-catalyzed Prins cyclization as the key transformation. The antiproliferative 
activity of these new pyrans against several cancer cell lines was then investigated. Among 
them, an isochromene with moderate activity (mean logGI50 = 0.91) was found. 
Additionally, compounds with selectivity toward the tumor cell lines NCI-ADR/RES, 
OVCAR-3, and HT29 were discovered. 
Keywords: osochromene; pyrans; Prins cyclization; iodine; antiproliferative; cancer 
 
1. Introduction 
Natural products have always played an important role in drug discovery [1–5]. Although it is not 
always possible to understand the exact function of the secondary metabolites isolated from natural 
sources, they are often used as inspiration for new drugs, particularly in the area of cancer [6–9]. The 
pyran subunit can be frequently recognized in the structure of numerous natural and synthetic 
compounds with remarkable biological and pharmacological properties [10–13]. Populene D (Figure 1) 
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is a natural sesquiterpenoid recently isolated from Thespesia populnea, which possesses strong 
inhibitory activity against several human cancer cell lines: cervical cancer (HeLa, IC50 = 1.85 µg/mL) 
and breast cancer (MCF-7, IC50 = 0.95 µg/mL) [14]. Populene D is also active against colon cancer 
(HT-29, IC50 = 2.37 µg/mL), oral cancer (KB, IC50 = 3.10 µg/mL) and has antibacterial properties  
(B. subtilis, MIC = 4.69 µg/mL) [14]. 
Figure 1. Structure of populene D. 
O
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HO
 
We envisioned that populene D analogues could be synthesized by the iodine-catalyzed Prins 
cyclization of homoallylic alcohols and acetone (Scheme 1) [15]. Considering that several homoallylic 
alcohols can be easily prepared from commercially available tetralones [16], this route could provide 
access to analogues of a natural compound with potential anticancer activity. Herein, we describe our 
first results regarding the concise synthesis of nine isochromenes and their antiproliferative activity 
against several tumor cell lines. 
Scheme 1. Retrosynthesis for populene D analogues. 
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2. Results and Discussion 
2.1. Synthesis of Populene D Analogues 
The homoallylic alcohols 1a–d were prepared in three steps from commercially available  
1-tetralones as previously reported [16]. The Prins cyclization of the homoallylic alcohols 1a–d and 
acetone in the presence of iodine gave the methoxy substituted populene D analogues 2a–d in 73–88% 
yield (Table 1, entries 1–4). The treatment of 2a–c with sodium ethanethiolate [17,18] gave hydroxy 
substituted populene D analogues 3a–c in 71–82% yield (Table 2, entries 1–3). Under analogous 
conditions, the dimethoxy substrate 2d gave the mono deprotected compound 3d in 42% yield (entry 4). 
The structure of 3d was assigned by NMR analysis, including HMBC experiments. The double 
deprotection to obtain 3e was achieved using excess of sodium ethanethiolate and longer reaction time 
(entry 5). In summary, nine new populene D analogues were efficiently prepared using as key reaction 
a Prins cyclization and fully characterized. 
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Table 1. Iodine-catalyzed Prins cyclization. 
OH O
1a-d 2a-e
acetone or Et2CO
5 mol% I2
CH2Cl2, rt
MeO MeO
 
Entry Homoallylic alcohols 1a–d Products 2a–e (yield)  
1 OH
1aOMe OMe
O
2a (80%)  
2 
MeO
OH
1b  2b (82%)
MeO
O
 
3 
1c
MeO
OH
 2c (73%)
MeO
O
 
4 
MeO
MeO
OH
1d 2d (88%)
MeO
MeO
O
 
Table 2. Cleavage of the ether moiety. 
O O
2a-e 3a-e
EtSH/NaH
DMF
MeO HO
 
Entry Substrates 2a–d Products 3a–e (yield) 
1 2a 
OH
O
3a (82%)
2 2b 
3b (79%)HO
O
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Table 2. Cont. 
O O
2a-e 3a-e
EtSH/NaH
DMF
MeO HO
 
Entry Substrates 2a–d Products 3a–e (yield) 
3 2c 
3c (71%)
HO
O
 
4 2d 
3d (42%)
HO
MeO
O
+ 3e (11%)  
5 2d 
3ea (76%)
HO
HO
O
 
a using excess of sodium ethanethiolate and longer reaction time. 
2.2. Antiproliferative Activity of Populene D Analogues 
The in vitro antiproliferative activity of populene analogues 2a–e and 3a–e was investigated toward 
nine human tumor cell lines [CNS (U251), breast (MCF-7), ovarian (NCI-ADR/RES, OVCAR-03), 
renal (786-0), non-small cell lung (NCI-H460), prostate (PC-3), colon (HT-29) and leukemia (k-562)] 
and one human normal cell line (HaCat, human keratinocytes). The populene D analogues were tested 
at concentrations between 0.25 and 250 µg/mL and doxorubicin (DOX 0.025–25 µg/mL) was used as 
positive control. Two effective concentrations, eliciting 50% growth inhibition (GI50) and total growth 
inhibition (TGI), were determined after 48 h-cell treatment (Tables 3 and 4). To analyze the GI50 
parameter, mean log GI50 was calculated by conversion of the GI50 values for each tumor cell line 
tested (not including the normal cell line HaCat) against a test compound and then these values were 
averaged. According to National Cancer Institute (NCI/EUA), if mean logGI50 < 1.50 a tested compound 
could be considered as active and might be classified as of weak (1.1 < mean logGI50 < 1.5), moderate  
(0 < mean logGI50 < 1.1) or potent (mean logGI50 < 0) activity [19]. Using these criteria, phenol 3e 
(mean logGI50 = 0.91) was the most active populene analogue synthetized, presenting a moderate 
cytostatic activity with low selective against human cell lines evaluated. On the other hand, 
heterocycles 3c and 3d presented similar general weak cytostatic effect (mean log GI50 = 1.15 and 
1.16, respectively), but compound 3c showed a high selectivity to the ovarian cell line OVCAR-3  
(GI50 = 1.8 µg/mL), whereas pyran 3d was selective for the ovarian expressing multidrug resistance 
phenotype (NCI/ADR-RES, GI50 = 5.2 µg/mL) and to colon (HT29, GI50 = 6.0 µg/mL) cell lines. 
Isochromenes 3a and 3b were considered inactive (mean logGI50 > 2.32 and > 2.00, respectively). The 
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methoxy derivatives 2a–c presented a weak cytostatic activity (mean logGI50 from 1.12 to 1.23), 
whereas compound 2d was inactive. However, the following differences in selectivity were found for 
these ethers: (i) pyran 2a is more selective to leukemia (K562, GI50 = 3.1 µg/mL); (ii) compound 2b 
was more active against colon (HT29, GI50 = 6.6 µg/mL) cell line; (iii) heterocycle 2e presented a 
slight selectivity to glioma (U251, GI50 = 6.3 µg/mL) cell line. 
In summary, these results suggest that the hydroxyl/methoxyl pattern of substitution has an 
important influence in the antiproliferative activity. Moreover, the dihydroxy-substituted populene D 
analogue 3e is the most active compound in the 2a–d and 3a–e series. Considering the 
monosubstituted compounds, the conversion of the methoxy (2a and 2b) into a hydroxy (3a and 3b) 
group resulted in lower activity, whereas the substitution from 2c to 3c led to a slightly increase in the 
cytostatic activity. Among the disubstituted compounds, the conversion of the methoxy (2d) to 
hydroxy (3d and 3e) increased the activity. 
The results obtained for the TGI parameter confirm the GI50 evaluation, indicating moderate activity 
for populene analogues 2a–2c and 3c–3e (Table 4). The evaluation for the normal human cell lines 
(HaCat) shows GI50 and TGI values on the same order of magnitude than for the tumor cell lines, 
suggesting that populene D analogues may present in vivo toxicity, similar to the known 
chemotherapic drugs. 
Table 3. Antiproliferative activity (GI50, μg/mL) of 2a–d and 3a–e on human cell lines. 
Cell lines a Doxorubicine b 2a 2b 2c 2d 3a 3b 3c 3d 3e 
U251 0.062 25.0 24.6 25.0 >250 >250 46.3 27.8 23.1 19.6 
MCF-7 0.21 25.0 23.2 25.0 38.8 >250 107.8 24.7 24.6 5.5 
NCI-
ADR/RES 
1.3 25.0 26.8 25.0 100.7 >250 >250 25.0 5.2 5.7 
786-0 0.04 25.0 25.5 25.0 45.8 37.3 36.8 24.6 24.1 5.6 
NCI-H460 <0.025 N.T. N.T. N.T. N.T. >250 41.4 24.2 45.1 17.4 
PC-3 0.27 25.0 27.0 25.0 71.4 >250 >250 24.5 N.T. N.T. 
OVCAR-3 0.26 25.0 24.5 25.0 193.4 >250 >250 1.8 24.3 3.9 
HT-29 0.22 25.0 6.6 25.0 23.1 >250 78.4 22.9 6.0 19.5 
K-562 0.4 3.1 9.6 25.0 84.6 >250 41.2 8.7 N.T. N.T. 
HaCat 0.23 25.0 26.1 25.0 >250 >250 >250 3.6 4.2 4.2 
Mean 
logGI50 c, d −0.78 P 
1.17 
W 
1.18 
W 
1.21 
W 
>1.70 
I 
>2.31 
I 
>1.95 
I 
1.22 
W 
1.24 
W 
0.95 
M 
N.T.: not tested. a Tumor cell lines: U251—glioma; MCF-7—mammary; NCI-ADR/RES—drug 
resistant ovary; 786-0—kidney; NCI-H460—lung; NCI-PC-3—prostate; OVCAR-3—ovary;  
HT-29 colon; K562—leukemia. Normal cell lines: HaCat—immortalized keratinocytes; b Positive 
control; c Mean logGI50: The GI50 value for each tumor cell line tested (not including the normal 
cell line HaCat) against a test compound is converted to its logGI50 value and these logGI50 values 
are averaged; d NCI’s criteria [19]: I: mean logGI50 > 1.5 = inactive; W, weak activity: 1.1 < mean 
logGI50 < 1.5; M, moderate activity: 0 < mean logGI50 < 1.1; P, potent activity: mean log GI50 < 0. 
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Table 4. Total growth inhibition (TGI, μg/mL) of 2a–d and 3a–e on human cell lines. 
Cell lines a Doxorubicine b 2a 2b 2c 2d 3a 3b 3c 3d 3e 
U251 1.1 52.0 53.5 40.0 >250 >250 >250 67.9 45.9 28.4 
MCF-7 8.8 51.3 46.9 45.3 >250 >250 >250 45.0 58.2 41.6 
NCI-
ADR/RES 25.0 83.5 104.4 66.3 >250 >250 >250 199.5 37.6 >250 
786-0 0.62 50.6 44.0 36.1 >250 >250 >250 43.0 47.8 19.4 
NCI-H460 0.025 N.T. N.T. N.T. N.T. >250 >250 45.9 >250 >250 
PC-3 4.4 64.6 41.4 69.2 >250 >250 >250 51.8 N.T. N.T. 
OVCAR-3 3.9 52.3 56.2 67.0 >250 >250 >250 31.5 69.9 34.4 
HT-29 25.0 39.1 33.0 41.8 >250 >250 >250 53.3 32.3 39.0 
K-562 25.0 >250 >250 128.1 >250 >250 >250 39.2 N.T. N.T. 
HaCat 0.67 66.9 54.4 32.0 >250 >250 >250 >250 160.7 >250 
N.T.: not tested; a Tumor cell lines: U251—glioma; MCF-7—mammary; NCI-ADR/RES—drug 
resistant ovary; 786-0—kidney; NCI-H460—lung; NCI-PC-3—prostate; OVCAR-3—ovary; HT-29 
colon; K562—leukemia. Normal cell lines: HaCat—immortalized keratinocytes. b Positive control. 
3. Experimental 
3.1. General 
All commercially available reagents were used without further purification unless otherwise noted. 
CH2Cl2 and DMF were freshly distilled over CaH2. TLC analyses were performed in silica gel plates, 
using UV and/or p-anisaldehyde solution for visualization. Flash column chromatography was 
performed using silica gel 200–400 mesh. Melting points are uncorrected. All NMR analyses were 
recorded using CDCl3 as solvent and TMS as internal pattern in Bruker (AC200) or Varian 
(INOVA300) spectrometers. IR spectra were measured on a Perkin-Elmer 1750-FT. HRMS analysis 
were performed on a Bruker Daltonics Microtof Eletrospray. Melting points were recorded on a Buchi 
R-535 apparatus and are uncorrected. The homoallylic alcohols 1a–c were prepared in three steps from 
commercially available 1-tetralones as previously reported [16]. 
3.2. General Procedure for Prins Cyclizations 
To a stirred solution of 1a–d (1.0 mmol) and (CH3)2CO (1.2 mmol) in CH2Cl2 (5 mL), was added I2 
(0.050 mmol). After 2 h, Na2SO3 (0.60 mmol) and H2O (10 mL) were added. The aqueous phase was 
extracted with AcOEt (3 × 5 mL). The combined organic phase was washed with brine (5 mL) and 
dried over anhydrous MgSO4. The solvent was removed under reduced pressure. The crude product 
was purified by flash column chromatography (5% AcOEt in hexanes), affording 2a–d. 
4,5,6-Tetrahydro-7-methoxy-1,4,4-trimethyl-1H-benzo[f]isochromene (2a). Yield: 80%. White solid; 
mp: 65–67 °C; IR (film): 3073, 2969, 1574, 1470, 1460, 784 cm−1; 1H-NMR (200 MHz, CDCl3) δ: 
1.23 (d, J = 6.8 Hz, 3H), 1.32 (s, 3H), 1.42 (s, 3H), 2.05–2.25 (m, 2H), 2.48–2.66 (m, 2H), 2.84–2.99 
(m, 1H), 3.65 (dd, J = 2.4, 11.1 Hz, 1H), 3.84 (s, 3H), 3.93 (dd, J = 3.3, 11.1 Hz, 1H), 6.78 (d,  
J = 8.3 Hz, 1H), 6.94 (d, J = 7.8 Hz, 1H), 7.19 (dd, J = 7.8, 8.2 Hz, 1H); 13C-NMR (50 MHz, CDCl3) 
δ: 18.2, 20.4, 23.9, 24.1, 27.9, 29.2, 55.5, 65.8, 74.8, 109.0, 115.3, 123.6, 126.4, 129.6, 135.2, 138.6, 
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155.9; LRMS m/z (rel. int.): 258 (M+, 9.1), 244 (13), 243 (100), 227 (15), 105 (35), 77 (53), 43 (66); 
HRMS [ESI(+)] calcd. for [C17H22O2+ H]+ 259.1693, found 259.1679. 
2,4,5,6-Tetrahydro-8-methoxy-1,4,4-trimethyl-1H-benzo[f]isochromene (2b). Yield: 82%. White solid; 
mp: 89.5–91.3 °C; IR (film): 3005, 2970, 1610, 1570, 1492, 1427, 670, 612 cm−1; 1H-NMR (200 MHz, 
CDCl3) δ: 1.21 (d, J = 6.8 Hz, 3H), 1.29 (s, 3H), 1.39 (s, 3H), 203–2.15 (m, 2H), 2.56–2.72 (m, 3H), 
3.62 (dd, J = 2.2, 11.1 Hz, 1H), 3.78 (s, 3H), 3.90 (dd, J = 3.3, 11.1 Hz, 1H), 6.69–6.75 (m, 2H), 7.16 
(d, J = 8.3 Hz, 1H); 13C-NMR (50 MHz, CDCl3) δ: 18.0, 24.0, 24.3, 27.9, 28.9, 29.0, 55.0, 65.6, 74.6, 
110.9, 113.4, 123.3, 126.9, 129.3, 135.7, 137.4, 157.9; LRMS m/z (rel. int.): 258 (M+, 9.9), 244 (13), 
243 (100); Elemental analysis calcd. for [C17H22O2] C 79.03, H 8.58, found C 78.61, H 8.37. 
2,4,5,6-Tetrahydro-9-methoxy-1,4,4-trimethyl-1H-benzo[f]isochromene (2c). Yield: 73%. Colorless 
viscous oil; IR (film): 3076, 2969, 1605, 1573, 1496, 1461, 835, 803 cm−1; 1H-NMR (200 MHz, CDCl3) 
δ: 1.23 (d, J = 6.8 Hz, 3H), 1.30 (s, 3H), 1.40 (s, 3H), 2.03–2.16 (m, 2H), 2.59–2.69 (m, 3H), 3.63 (dd,  
J = 2.4, 11.2 Hz, 1H), 3.79 (s, 3H), 3.91 (dd, J = 3.2, 11.2 Hz, 1H), 6.67 (dd, J = 2.4, 8.1 Hz, 1H), 6.84 
(d, J = 2.4 Hz, 1H), 7.03 (d, J = 8.1 Hz, 1H); 13C-NMR (50 MHz, CDCl3) δ: 18.0, 24.1, 24.9, 27.7, 27.8, 
28.9, 55.2, 65.7, 74.8, 109.3, 110.3, 127.8, 128.0, 129.7, 135.1, 139.2, 158.4; LRMS m/z (rel. int.): 258 
(M+, 11.5), 244 (14), 243 (100); HRMS [ESI(+)] calcd. for [C17H22O2+ H]+ 259.1693, found 259.1699. 
2,4,5,6-Tetrahydro-8,9-dimethoxy-1,4,4-trimethyl-1H-benzo[f]isochromene (2d). Yield: 81%. White 
solid; mp: 115–117 °C; IR (film): 2968, 2931, 1512, 1238, 1203, 856, 806 cm−1; 1H-NMR (200 MHz, 
CDCl3) δ: 1.24 (d, J = 6.8 Hz, 3H), 1.30 (s, 3H), 1.40 (s, 3H), 2.04–2.17 (m, 2H), 2.58–2.70 (m, 3H), 
3.64 (dd, J = 2.2, 11.2 Hz, 1H), 3.88 (s, 3H), 3.90–3.96 (m, 1H), 6.69 (s, 1H), 6.83 (s, 1H); 13C-NMR 
(50 MHz, CDCl3) δ: 18.1, 24.1, 24.7, 28.0,28.3, 29.1, 55.9, 56.2, 65.6, 74.8, 106.9, 111.2, 126.7, 
128.5, 129.2, 136.4, 147.2, 147.3; LRMS m/z (rel. int.): 288 (M+, 22), 274 (17), 273 (100); CH analysis 
calcd. for [C18H24O3] C 74.97, H 8.39, found C 74.77, H 8.75. 
3.3. General Procedure for the Deprotections of 3a–d 
Under an inert atmosphere of N2, NaH (17.5 mmol, 60% in mineral oil) was washed with anhydrous 
hexanes (2 × 10 mL). After a few minutes, anhydrous DMF (5 mL) was added. To this mixture was 
slowly added a solution of EtSH (12.6 mmol) in anhydrous DMF (0.4 mL) at 0 °C and the resulting 
yellow gray solution was stirred for 20 min at rt. A solution of 2a–d (0.39 mmol) in DMF (1 mL) was 
then added dropwise and the resulting mixture was stirred for 5 h at 140 °C, becoming slightly brown. 
The mixture was cooled to the rt and a saturated solution of NH4Cl (5 mL) was added. The mixture 
was extracted with Et2O (3 × 10 mL) and the organic phase was washed with H2O (5 mL), with brine 
(5 mL), and dried over anhydrous MgSO4. The solvent was removed under reduced pressure and the 
resulting brown oil was purified by flash chromatography (30% AcOEt in hexanes), affording 3a–d. 
1,4,4-Trimethyl-1,4,5,6-tetrahydro-2H-benzo[f]isochromen-7-ol (3a). Yield: 82%. White solid; mp: 
139.2–140.3 °C; IR (film): 3289, 2971, 2932, 1578, 1468, 916, 833 cm−1; 1H-NMR (200 MHz, CDCl3) 
δ: 1.22 (d, J = 6.8 Hz, 3H), 1.32 (s, 3H), 1.42 (s, 3H), 2.05–2.25 (m, 2H), 2.49–2.65 (m, 2H),  
2.80–2.91 (m, 1H), 3.64 (dd, J = 2.3, 11.1 Hz, 1H), 3.92 (dd, J = 3.3, 11.1 Hz, 1H), 6.67 (d, J = 0.6, 
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7.9 Hz, 1H), 6.90 (d, J= 7.6 Hz, 1H), 7.09 (dd, J = 7.8, 8.0 Hz, 1H); 13C-NMR (50 MHz, CDCl3) δ: 
18.2, 20.5, 23.8, 24.1, 27.9, 29.2, 65.8, 74.8, 113.8, 115.6, 121.2, 126.6, 129.9, 135.6, 138.5, 151.9; 
LRMS m/z (rel. int.): 244 (M+, 9.0), 230 (13), 229 (100); CH analysis calcd. for [C16H21O2] C 78.65, H 
8.25, found C 78.45, H 8.00. 
1,4,4-Trimethyl-1,4,5,6-tetrahydro-2H-benzo[f]isochromen-8-ol (3b). Yield: 79%. White solid; mp: 
199–201 °C; IR (film): 3350, 2968, 2932, 1605, 1502, 1440, 849, 834 cm−1; 1H-NMR (200 MHz, 
CDCl3) δ: 1.22 (d, J = 6.8 Hz, 3H), 1.31 (s, 3H), 1.40 (s, 3H), 2.08–2.16 (m, 2H), 2.57–2.71 (m, 3H), 
3.64 (dd, J = 2.3, 11.2 Hz, 1H), 3.93 (dd, J = 3.2, 11.2 Hz, 1H),5.13 (s, 1H), 6.64–6.70 (m, 2H), 7.12 
(d, J = 8.1 Hz, 1H); 13C-NMR (50 MHz, CDCl3) δ: 18.1, 24.1, 24.4, 28.0, 28.9, 29.0, 65.7, 74.9, 112.7, 
114.7, 123.7, 127.1, 129.4, 135.8, 137.9, 154.1; LRMS m/z (rel. int.): 244 (M+, 9.8), 230 (15), 229 
(100); CH analysis calcd. for [C16H21O2] C 78.65, H 8.25, found C 78.19, H 8.04. 
1,4,4-Trimethyl-1,4,5,6-tetrahydro-2H-benzo[f]isochromen-9-ol (3c). Yield: 71%, White solid; mp: 
160–162 °C; IR (film): 3235, 2962, 2943, 1615, 1572, 1497, 834, 809 cm−1; 1H-NMR (200 MHz, 
CDCl3) δ: 1.21 (d, J = 6.8 Hz, 3H), 1.35 (s, 3H), 1.45 (s, 3H), 2.17–2.08 (m, 2H), 2.69–2.55 (m, 3H), 
3.65 (dd, J = 11.1, 2.4 Hz, 1H), 3.93 (dd, J = 11.1, 3.3 Hz, 1H), 6.64 (dd, J = 7.8, 2.4 Hz, 1H), 6.79 (d, 
J = 2.4 Hz, 1H), 6.98 (d, J = 7.8 Hz, 1H); 13C-NMR (50 MHz, CDCl3) δ: 18.0, 24.2, 24.9, 27.69, 27.74, 
28.9, 65.6, 75.4, 109,9, 112.8, 127.5, 128.1, 129.6, 135.1, 138.8, 154.6; LRMS m/z (rel. int.): 244 (M+, 9.3), 
230 (15), 229 (100); HRMS [ESI(+)] calcd. for [C16H20O2+ Na]+ 267.1355, found. 267.1359. 
8-Methoxy-1,4,4-trimethyl-1,4,5,6-tetrahydro-2H-benzo[f]isochromen-9-ol (3d). Yield: 42%. Pale 
yellow solid; mp: 141–143 °C; IR: 3396, 2967, 2924, 1509, 869, 809 cm−1; 1H-NMR (200 MHz, 
CDCl3) δ: 1.23 (d, J =7.2 Hz, 3H), 1.30 (s, 3H), 1.40 (s, 3H), 2.05–2.14 (m, 2H), 2.56–2.66 (m, 3H), 
3.66 (dd, J = 2.2, 11.1 Hz, 1H), 3.89 (s, 3H), 3.89–3.96 (m, 1H), 5.60 (br, 1H), 6.69 (d, J = 12.2 Hz, 
1H), 6.83 (d, J = 18.2 Hz, 1H); 13C-NMR (50 MHz, CDCl3) δ: 18.1, 24.1, 24.7, 28.0, 28.1, 29.2, 56.3, 
65.7, 74.9, 106.1, 109.5, 110.5, 114.1, 126.4, 129.3, 129.4, 136.3, 144.0, 144.9; LRMS m/z (rel. int.): 274 
(15.8), 260 (13.1), 259 (100); HRMS [ESI(+)] calcd. for [C17H22O3+ H]+ 275.1642, found 275.1648. 
1,4,4-Trimethyl-1,4,5,6-tetrahydro-2H-benzo[f]isochromene-8,9-diol (3e). The reaction was performed 
following the general procedure of Section 3.3, but using NaH (23 mmol), EtSH (18 mmol), 2d (0.144, 
0.500 mmol). Yield: 76%. Pale yellow solid; mp: 122–123 °C; IR (film): 3605, 3533, 2876, 2828, 
1619, 1601, 959, 939, 896, 687 cm−1; 1H-NMR (300 MHz, CDCl3) δ: 1.18 (d, J = 6.8 Hz, 3H), 1.32 (s, 
3H), 1.42 (s, 1H), 2.08–2.13 (m, 2H), 2.55–2.62 (m, 3H), 3.64 (dd, J = 2.4, 11.2 Hz, 1H), 3.92 (dd, J = 3.2, 
11.2 Hz, 1H), 3.67 (br, 2H), 6.67 (s, 1H), 6.81 (s, 1H); 13C-NMR (75 MHz, CDCl3) δ: 18.1, 24.1, 24.7, 
28.0, 28.1, 29.1, 65.7, 110.3, 114.7, 127.2, 128.8, 129.3, 136.2, 141.9, 142.0; LRMS m/z (rel. int.): 260 
(M+, 10), 246 (13), 245 (100); HRMS [ESI(+)] calcd. for [C16H19O3+ Na]+ 283.1305, found 283.1316. 
3.4. Antiproliferative Assays 
Human tumor cell lines [U251 (glioma), MCF-7 (breast), NCI-ADR/RES (ovarian expressing 
phenotype multiple drugs resistance), 786–0 (renal), NCI-H460 (lung, non-small cells), PC-3 
(prostate), OVCAR-03 (ovarian) and HT-29 (colon)] were kindly provided by Frederick Cancer 
Research & Development Center–National Cancer Institute–Frederick, MA, USA. HaCat cell line 
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(immortalized human keratinocytes) was kindly donated by Dr. Ricardo Della Coletta, FOP–Unicamp. 
Stock cultures were grown in 5 mL of RPMI 1640 (GIBCO BRL, Life Technologies) supplemented 
with 5% of fetal bovine serum. Penicillin:streptomycin (1,000 μg mL−1:1,000 UI mL-1, 1 mL L−1) was 
added to the experimental cultures. 
Cells in 96-well plates (100 μL cells/well) were exposed to various concentrations of compounds 
2a–d and 3a–d diluted in DMSO (0.25, 2.5, 25 and 250 μg/mL) at 37 C, 5% of CO2 for 48 h. The final 
concentration of DMSO did not affect the cell viability. Afterwards cells were fixed with 50% 
trichloroacetic acid and cell proliferation determined by spectrophotometric quantification (540 nm) of 
cellular protein content using sulforhodamine B assay[20]. Doxorubicin (0.025–25 g/mL) was used as 
positive control. Three measurements were obtained at the beginning of incubation (time zero, T0) and 48 h 
post-incubation for compound-free (C) and tested (T) cells. Cell proliferation was determined according to 
the equation 100 × [(T − T0)/C − T0], for T0 < T ≤ C, and 100 × [(T − T0)/T0], for T ≤ T0 and a 
concentration-response curve for each cell line was plotted and, from these curves, GI50 (concentration 
causing 50% growth inhibition) and TGI (concentration that promotes total growth inhibition) were 
determined by means of non-linear regression analysis using software ORIGIN 8.0 (OriginLab 
Corporation) [20,21] The average activity (mean of log GI50) of each compound tested was also determined 
using MS Excel software. Compounds were regarded as inactive (mean > 1.5), weakly (1.1 < mean < 1.5), 
moderately (0 < mean < 1.1) or potently (mean < 0) active on basis of the NCI criteria for the mean of 
logGI50 [19]. 
4. Conclusions 
In conclusion, the efficient synthesis of nine new populene D analogues 2a–d and 3a–e was 
performed using an iodine catalyzed Prins cyclization as key transformation. The antiproliferative 
activity of these compounds against several cancer cell lines was investigated. This evaluation 
demonstrated that isochromene 3e is the most active compound on the cell lines used. Although the 
populene D analogues do not display potent antiproliferative activity, we think this work might inspire 
the discovery of new highly active isochromenes. 
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